#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But where's the big buy-in?

It’s clear from #AS­CO22 that bio­phar­ma au­di­ences are back, live, at the big con­fer­ences. That’s en­cour­ag­ing, as we re­turn to more face-to-face meet­ings to ad­vance the work at hand. But go be­hind the busy cen­ter stage, and you’ll see plen­ty of wor­ry­ing signs that biotech — though not Big Phar­ma — is in for a rough ride. And just when it ends is any­one’s guess right now.

Sen­ti­ment is one thing, da­ta an­oth­er. And there’s no deny­ing that the num­bers have changed dra­mat­i­cal­ly. We asked Deal­For­ma chief Chris Doko­ma­ji­lar to crunch the num­bers a lit­tle bit ear­ly for H1, in or­der to get a look at the trends in play here dur­ing a wa­ter­shed year for the biotech in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER